Head to Head Review: Spectaire (NASDAQ:SPEC) versus Callitas Health (OTCMKTS:MPHMF)

Callitas Health (OTCMKTS:MPHMF) and Spectaire (NASDAQ:SPEC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Callitas Health and Spectaire, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Callitas Health	0	0	0	0	0.00
Spectaire	0	1	0	0	2.00

Spectaire has a consensus price target of $2.50, suggesting a potential upside of 4,900.00%. Given Spectaire’s stronger consensus rating and higher possible upside, analysts plainly believe Spectaire is more favorable than Callitas Health.

Profitability

This table compares Callitas Health and Spectaire’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Callitas Health	N/A	N/A	N/A
Spectaire	N/A	-81.22%	304.57%

Risk & Volatility

Callitas Health has a beta of -3.5, suggesting that its stock price is 450% less volatile than the S&P 500. Comparatively, Spectaire has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500.

Earnings & Valuation

This table compares Callitas Health and Spectaire”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Callitas Health	$530,000.00	N/A	-$1.28 million	N/A	N/A
Spectaire	N/A	N/A	$8.95 million	N/A	N/A

Spectaire has lower revenue, but higher earnings than Callitas Health.

Institutional & Insider Ownership

26.6% of Spectaire shares are owned by institutional investors. 25.4% of Spectaire shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Spectaire beats Callitas Health on 7 of the 9 factors compared between the two stocks.

About Callitas Health

Callitas Health, Inc. is a clinical stage company. It engages in the development of technologies for obesity, weight management, and female health and wellness. The company focuses on developing technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. It launched product ToConceive in North America. The firm researches, develops and business development processes for its other OTC products, CannaMint strips and orphan drug technologies. Callitas Health was founded on March 11, 2003 and is headquartered in Newport, KY.

About Spectaire

Spectaire Holdings Inc. provides solutions that measure, manage, and reduce carbon dioxide equivalent and other greenhouse gas emissions. The company offers AireCore, an integrated hardware, software, and data platform for logistics and supply chain players that uses mass spectrometry to directly measure their emissions. It serves the logistics, energy, agriculture, academics, and indoor air industries. The company is based in Watertown, Massachusetts.